Your search for tofacitinib returned 15 results

Cycling to a different tumor necrosis factor alpha inhibitor (TNFi) after treatment failure in patients with rheumatoid arthritis (RA) can be effective.

Patients with rheumatoid arthritis and diabetes mellitus had no increase in mean fasting blood glucose levels after 3 months of treatment with tofacitinib, a novel oral Janus kinase inhibitor, according to a pooled analysis of five phase 3 trials reported at the 2013 ACR/ARHP Annual Meeting.

Tofacitinib 5mg or 10mg twice daily showed a consistent safety profile and sustained efficacy over 5 years in long-term extension studies for patients with rheumatoid arthritis, as presented at the 2013 ACR/ARHP Annual Meeting.

Tofacitinib may be a viable option for patients with moderate-to-severe rheumatoid arthritis, according to a systematic review and meta-analysis reported at the 2013 ACR/ARHP Annual Meeting.

Changing directly from adalimumab to tofacitinib sustained clinical response and improved ACR response rates in patients with rheumatoid arthritis, an open-label extension study presented at the 2013 ACR/ARHP Annual Meeting has found.